These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31861748)

  • 1. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.
    Di Martino MT; Arbitrio M; Fonsi M; Erratico CA; Scionti F; Caracciolo D; Tagliaferri P; Tassone P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861748
    [No Abstract]   [Full Text] [Related]  

  • 2. Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation.
    Fonsi M; Fulbert J; Billat PA; Arbitrio M; Tagliaferri P; Tassone P; Di Martino MT
    Curr Res Pharmacol Drug Discov; 2024; 7():100197. PubMed ID: 39188553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
    Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
    Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
    Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
    Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA.
    Kumar R; Singh SK; Koshkin AA; Rajwanshi VK; Meldgaard M; Wengel J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2219-22. PubMed ID: 9873516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LNA-mediated microRNA silencing in non-human primates.
    Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
    Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies.
    Javanmard SH; Vaseghi G; Ghasemi A; Rafiee L; Ferns GA; Esfahani HN; Nedaeinia R
    Cancer Cell Int; 2020; 20():384. PubMed ID: 32788885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-20a inhibition using locked nucleic acid (LNA) technology and its effects on apoptosis of human macrophages infected by Toxoplasma gondii RH strain.
    Rezaei F; Daryani A; Sharifi M; Sarvi S; Jafari N; Pagheh AS; Hashemi N; Hejazi SH
    Microb Pathog; 2018 Aug; 121():269-276. PubMed ID: 29800695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial observations of 99mTc labelled locked nucleic acids for antisense targeting.
    Zhang Y; He J; Liu G; Venderheyden JL; Gupta S; Rusckowski M; Hnatowich DJ
    Nucl Med Commun; 2004 Nov; 25(11):1113-8. PubMed ID: 15577590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.
    Santolla MF; Lappano R; Cirillo F; Rigiracciolo DC; Sebastiani A; Abonante S; Tassone P; Tagliaferri P; Di Martino MT; Maggiolini M; Vivacqua A
    J Exp Clin Cancer Res; 2018 May; 37(1):94. PubMed ID: 29716623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.
    Franzoni S; Vezzelli A; Turtoro A; Solazzo L; Greco A; Tassone P; Di Martino MT; Breda M
    J Pharm Biomed Anal; 2018 Feb; 150():300-307. PubMed ID: 29268195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.
    Elmén J; Lindow M; Silahtaroglu A; Bak M; Christensen M; Lind-Thomsen A; Hedtjärn M; Hansen JB; Hansen HF; Straarup EM; McCullagh K; Kearney P; Kauppinen S
    Nucleic Acids Res; 2008 Mar; 36(4):1153-62. PubMed ID: 18158304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.